Since several independent observations indicate that ICAM-1 is highly expressed and involved in the pathogenesis of myeloma, it constitutes an attractive novel target for immunotherapy of multiple myeloma [14–16]. This evidence concerns the gene ICAM1 and plasma cell myeloma.